Collegium Pharmaceutical (COLL) Current Deferred Revenue (2014 - 2026)

Collegium Pharmaceutical's Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $667000.0 for Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 97.63% year-over-year to $667000.0 in Q1 2026; TTM through Mar 2026 was $667000.0, a 97.63% decrease from a year earlier, with the FY2025 full-year figure at $667000.0, down 99.55% from the prior year.
• Current Deferred Revenue steadied at $667000.0 in Q1 2026 per COLL's latest filing, from $667000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $167.5 million in Q3 2023 and bottomed at $667000.0 in Q3 2025.
• The 5-year median for Current Deferred Revenue is $51.3 million (2022), against an average of $68.0 million.
• Across the five-year window, Current Deferred Revenue soared 89.84% in 2024 and slumped 99.55% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $73.6 million in 2022, then increased by 5.37% to $77.5 million in 2023, then jumped by 89.84% to $147.1 million in 2024, then slumped by 99.55% to $667000.0 in 2025, then changed by 0.0% to $667000.0 in 2026.
• Per Business Quant, the three latest COLL Current Deferred Revenue figures stand at $667000.0 (Q1 2026), $667000.0 (Q4 2025), and $667000.0 (Q3 2025).